Spots Global Cancer Trial Database for Ph II Study of Perifosine Plus Gleevec for Patients With GIST

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Ph II Study of Perifosine Plus Gleevec for Patients With GIST

Official Title: A Phase II Study of Perifosine Plus Imatinib Mesylate for Patients With Resistant Gastrointestinal Stromal Tumor

Study ID: NCT00455559

Conditions

Gastrointestinal Stromal Tumors

Interventions

Perifosine

Imatinib Mesylate

Study Description

Brief Summary: This is a Phase II trial designed to determine the efficacy and safety of perifosine plus imatinib mesylate in patients with advanced GIST who develop progressive disease or recurrence while receiving imatinib mesylate.

Detailed Description: This is a Phase II study of perifosine in combination with imatinib mesylate in patients with advanced GIST. Each cycle lasts 28 days. There will be two treatment arms. On both arms, patients will continue the dose of imatinib mesylate taken during the period of disease progression. Patients will be randomized to one either a weekly or a daily perifosine treatment regimen at the time of registration.